Trending...
- wine2wine Vinitaly Business Forum 2025: Equipping the wine industry with the tools to face an uncertain future - 156
- September Career Reset - How Job Seekers Are Using WIOA to Pivot Before Year-End - 125
- CCHR: For Prevention, Families Deserve Truth From NIH Study on Psychiatric Drugs - 120
EVANSTON, Ill.--(BUSINESS WIRE)--A new in vitro study done collaboratively by Utah State University and Northwestern University finds Xlear components (grapefruit seed extract and xylitol) significantly eliminates SARS-CoV-2, the virus that causes COVID-19. The imaging research study component was performed at the BioCryo facility of Northwestern University's NUANCE Center.
The study tested SARS-CoV-2 virus titers and LRV against a single concentration of Xlear nasal spray. According to the Study, "After a 25-minute contact time, the nasal spray reduced virus from 4.2 to 1.7 log10 CCID50 per 0.1 mL, a statistically significant reduction (P<0.001) of 2.5 log10 CCID50." The Northwestern/Utah State Study is the newest in a string of studies to reach the conclusion that Xlear is effective against the SARS-CoV-2.
However, the study breaks new ground in two vital respects: "First, we conclude, in addition to countering SARS-CoV-2, Xlear is likely effective in preventing the spread of future H1N1 viruses, including the emerging SARS-CoV-2 variants, along with other viral epidemics. Given the more transmissible variants we now face, this is critical now," said Professor Mark Cannon, Feinberg School of Medicine, Northwestern University. "Second, using electron microscopy, we have visual evidence showing that xylitol and GSE counters the virus. The GSE kills the virus, while the xylitol prevents the virus from attaching to the cell walls. The image (attached) shows SARS-CoV-2 viruses outside the cell and never attached, thereby preventing infection," added Dr. Cannon. The study postulates that xylitol acts as a decoy target for SARS-CoV-2, preventing virus attachment to the core protein on the cell wall.
More on illi News
The collaborative study concludes: "Because there are no risk factors in using the X/GSE combination therapy, and [Xlear] nasal spray is over the counter available without prescription, and [Xlear] allows for comfortable long term mask wearing, adoption of this preventive anti-viral therapy should be encouraged."
Full study: https://www.biorxiv.org/content/10.1101/2020.12.02.408575v3.full
For more information on Xlear (including where to obtain): https://xlear.com/
The study tested SARS-CoV-2 virus titers and LRV against a single concentration of Xlear nasal spray. According to the Study, "After a 25-minute contact time, the nasal spray reduced virus from 4.2 to 1.7 log10 CCID50 per 0.1 mL, a statistically significant reduction (P<0.001) of 2.5 log10 CCID50." The Northwestern/Utah State Study is the newest in a string of studies to reach the conclusion that Xlear is effective against the SARS-CoV-2.
However, the study breaks new ground in two vital respects: "First, we conclude, in addition to countering SARS-CoV-2, Xlear is likely effective in preventing the spread of future H1N1 viruses, including the emerging SARS-CoV-2 variants, along with other viral epidemics. Given the more transmissible variants we now face, this is critical now," said Professor Mark Cannon, Feinberg School of Medicine, Northwestern University. "Second, using electron microscopy, we have visual evidence showing that xylitol and GSE counters the virus. The GSE kills the virus, while the xylitol prevents the virus from attaching to the cell walls. The image (attached) shows SARS-CoV-2 viruses outside the cell and never attached, thereby preventing infection," added Dr. Cannon. The study postulates that xylitol acts as a decoy target for SARS-CoV-2, preventing virus attachment to the core protein on the cell wall.
More on illi News
- A New Era in Healthcare Marketing
- Chicago: Mayor Brandon Johnson Signs 'Right to Protest' Executive Order
- Sloan's Lake Dental Launches New Website to Enhance Patient Experience and Access to Modern Dental Care
- Only 3 Weeks Left till the Start of the OpenSSL Conference 2025
- InventHelp Inventor Develops Portable Sit-On-Scale (CLR-320)
The collaborative study concludes: "Because there are no risk factors in using the X/GSE combination therapy, and [Xlear] nasal spray is over the counter available without prescription, and [Xlear] allows for comfortable long term mask wearing, adoption of this preventive anti-viral therapy should be encouraged."
Full study: https://www.biorxiv.org/content/10.1101/2020.12.02.408575v3.full
For more information on Xlear (including where to obtain): https://xlear.com/
Filed Under: Business
0 Comments
Latest on illi News
- Matecrypt Observes South American Cryptocurrency Adoption Surge Amid Economic Shifts
- Assent Uncovers Over 695 Unique PFAS Across Global Supply Chains as Regulations Increase
- Cryptocurrency Quarterly Trading Volume Surpasses $15 Trillion Record High as BrazilNex Acknowledges Industry 'Growing Pains' Amid Market Speculation
- Simpli.fi Earns Finalist Honors in the 2025 AdExchanger Awards
- Cyrus O'Leary's Introduces Cookie Dough Pybrid for Foodservice, Giving Chefs a Blank Canvas for Signature Desserts
- AHRFD Initiates Legal Proceedings Against Anwalt.de for Publishing Defamatory and False Content
- New Analysis Reveals the Complex Forces Driving the 'Great Human Reshuffle'
- Elevate Unveils GroundComm X30 at 2025 International GSE Expo in Las Vegas
- Homeless Man Charged with String of Business Burglaries in Naperville
- NEW power supply release from Kepco Dynatronix - HSP Advanced
- St. Augustine Honors Hispanic Heritage Month
- Vesica Health Receives AUA Guideline Inclusion
- Steward's Plumbing Sponsors the 2025 Samson Challenge, Bringing Community, Fitness, and Fun Together in Albuquerque
- Mondo named endorsed turf partner by United States Padel Association
- The Emotional Weight of Foreclosure—and Why No One Should Go Through It Alone
- Chicago: Mayor Brandon Johnson Announces Request for South Lawndale Small Business Storefront Activation Project
- 10xLaw.com Extends Employment Opportunity to Kim Kardashian
- 1 Man vs GOAT.com and Latham & Watkins LLP: GOAT SKIN CHICAGO (GSC) Fights Back in Trademark Battle
- DecisionPoint Technologies Accelerates Growth with Acquisition of Acuity Technologies
- CCHR: Involuntary Commitment Is Eugenics Repackaged as "Mental Health Care"